Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Bortezomib + Dexamethasone + Pomalidomide
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Bortezomib Velcade Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).
Dexamethasone Adexone Desametasone
Pomalidomide Pomalyst CC-4047 Pomalyst (pomalidomide) is a thalidomide derivative that inhibits angiogenesis and modulates immune response, potentially lead to antitumor activity (PMID: 30069630). Pomalyst (pomalidomide) is FDA approved for use in patients with Kaposi's sarcoma who failed HAART or are HIV-negative, and in combination with dexamethasone in patients with multiple myeloma who had 2 or more prior therapies (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04484623 Phase III Bortezomib + Dexamethasone + Pomalidomide belantamab mafodotin-blmf + Dexamethasone + Pomalidomide Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8) Recruiting USA | TUR | POL | NZL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | BRA | AUS 4
NCT05519085 Phase III Bortezomib + Dexamethasone + Pomalidomide Bortezomib + CC-92480 + Dexamethasone A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (Successor-1) Recruiting USA | TUR | ROU | POL | NZL | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG 7
NCT04181827 Phase III Daratumumab + Dexamethasone + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide Bortezomib + Ciltacabtagene autoleucel + Cyclophosphamide + Dexamethasone + Fludarabine + Pomalidomide Ciltacabtagene autoleucel + Cyclophosphamide + Daratumumab + Dexamethasone + Fludarabine + Pomalidomide A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4) Active, not recruiting USA | SWE | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | BEL | AUS 2
NCT05572515 Phase III Teclistamab Carfilzomib + Dexamethasone Bortezomib + Dexamethasone + Pomalidomide A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9) Recruiting USA | TUR | SWE | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS 5
NCT06152575 Phase III Dexamethasone + Elotuzumab + Pomalidomide Carfilzomib + Dexamethasone Bortezomib + Dexamethasone + Pomalidomide Elranatamab-bcmm MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Recruiting USA | SWE | NOR | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | ARG 1
NCT06208150 Phase III Dexamethasone + Elotuzumab + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide Talquetamab-tgvs + Teclistamab Pomalidomide + Talquetamab-tgvs Dexamethasone A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6) Recruiting USA | TUR | SWE | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG 5
NCT05675319 Phase III Bortezomib + Daratumumab + Dexamethasone Carfilzomib + Dexamethasone + Lenalidomide belantamab mafodotin-blmf + Daratumumab + Dexamethasone + Lenalidomide Dexamethasone + Elotuzumab + Lenalidomide Bortezomib + Dexamethasone + Pomalidomide Dexamethasone + Ixazomib + Lenalidomide Carfilzomib + Daratumumab + Dexamethasone Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (AlloRelapseMM) Recruiting DEU 0
NCT06413498 Phase III Cyclophosphamide + Fludarabine Carfilzomib + Daratumumab + Dexamethasone Daratumumab + Dexamethasone + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide CART-ddBCMA Carfilzomib + Dexamethasone A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3) Recruiting USA 0
NCT01728259 Phase I Bortezomib + Dexamethasone + Pomalidomide First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD Terminated USA | CAN 0


Additional content available in CKB BOOST